ACCRUFeR® assigned Priority Review in US by FDA

AI SummaryClose X

Shield Therapeutics announced that the FDA has accepted ACCRUFeR/FeRACCRU as a Clinical Supplement and granted Priority Review to extend its indication to adolescents aged 10 years and above. This follows positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) confirming the efficacy, safety, and tolerability of a new oral liquid pediatric formulation in children with iron deficiency anemia (IDA). Pending successful review, approval in the US is anticipated in 2026. Shield also plans to file for a further extension to include children 1 month and above, submitting an NDA for a new pediatric formulation (ferric maltol suspension) used in the FORTIS Phase 3 study. Norgine B.V., Shield's EU licensing partner, also filed a regulatory submission to the EMA in Q2 2025 for FeRACCRU approval in adolescents, with anticipated approval in 2026.

Disclaimer*

UK 100

Latest directors dealings